Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 67   

Articles published

PFE 32.72 -0.19 (-0.58%)
price chart
Is Pfizer A Good Buy?
Price is what you pay, value is what you get. If you are a long term investor then you may want to buy companies that can keep growing and keep returning more value for your buck.
PFE Breaking Out After Long Series of Corrections
Pfizer Inc. (NYSE:PFE) - This is the world's largest pharmaceutical company producing a wide range of drugs. In October 2009, it acquired Wyeth.
Pfizer sued by retailers for generic Lipitor delay
Five big U.S. retailers filed an antitrust lawsuit against Pfizer Inc and India's Ranbaxy Laboratories Ltd on Thursday, accusing them of conspiring to delay sales of generic versions of Lipitor, the best-selling drug in history.
Retailers sue Pfizer, charge generic Lipitor delay  Inquirer.net
Pharmacies Sue Pfizer Over Lipitor  Wall Street Journal
Pfizer Posts Strong Profits, Faces Strong Headwinds
Steps are being made in a positive direction, as Pfizer plans to spin off up to 20 percent of its animal health business in an initial public offering (IPO) this August. The goal at that point, according to CEO Ian Read, is to then focus the company on ...
Pfizer IPO, Cost Cuts Yield Time to Reinvent Its Research  Bloomberg
Business Day|Cost-Cutting Helps Pfizer Beat Analysts' Expectations  New York Times
Pfizer yanks breast, colon claims for Centrum vitamins
"The company disagrees with CSPI's concerns, but has agreed to make these changes in order to fully resolve the issues raised by the organization," Pfizer said in a statement provided on Thursday. A company spokesman declined to elaborate when asked ...
Pfizer to remove "breast health" and "colon health" ...  CBS News
Centrum Drops Breast And Colon Health Claims Amid Deceptive Advertising ...  Huffington Post
For Pfizer, Boston's medical labs a lure
Pfizer Inc., the world's largest pharmaceutical company, has a storied history of hunting for blockbuster drugs in its own labs.
Pfizer Announces Topline Results Of First Of Four Studies In Bapineuzumab ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the co-primary clinical endpoints, change in cognitive and functional performance compared to placebo, were not met in the Janssen Alzheimer Immunotherapy R&D LLC ...
Hopes dim for Alzheimer's trials after Pfizer failure  Reuters
Pfizer-Janssen Alzheimer's Treatment Misses Phase III Endpoints  Genetic Engineering News
Verastem Acquires Clinical-Stage FAK Inhibitor from Pfizer
BUSINESS WIRE)--Verastem, Inc., (NASDAQ: VSTM) a biopharmaceutical company focused on discovering and developing drugs to treat breast and other cancers by targeting cancer stem cells, announced an agreement with Pfizer for the exclusive ...
Verastem Inks Separate Deals for Wnt and FAK Inhibitors  Genetic Engineering News
Judge Rules Pfizer's Lyrica Patents Are Valid
Law360, New York (July 19, 2012, 10:12 PM ET) -- The patents for Pfizer Inc.'s blockbuster nerve pain drug Lyrica are valid, meaning Teva Pharmaceuticals Industries Ltd.
Pfizer Wins Lyrica Patent Ruling  Wall Street Journal
Pfizer Loses Prempro Ruling, Must Pay $10.4 Million
Jurors properly awarded Audrey Singleton, who sued Pfizer's Wyeth unit over Prempro, compensatory and punitive damages for the company's marketing of the drug, the Pennsylvania Superior Court ruled yesterday. Singleton's lawyers alleged that Wyeth hid ...